Apolipoprotein L1

• 

  Subject Areas on Research

  • A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis. 
  • A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. 
  • APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. 
  • APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis. 
  • APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It? 
  • APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. 
  • APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. 
  • APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. 
  • APOL1 risk alleles among individuals with CKD in Northern Tanzania: A pilot study. 
  • APOL1 variants in HIV-associated nephropathy: just one piece of the puzzle. 
  • APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. 
  • APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease. 
  • APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy. 
  • APOL1-associated kidney disease in northern Nigerians with treated HIV infection. 
  • APOL1: a case in point for replacing race with genetics. 
  • Apolipoprotein L1 (APOL1) Coding Variants Are Associated With Creatinine Rise After Cardiac Surgery. 
  • Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. 
  • Apolipoprotein-1 risk variants and associated kidney phenotypes in an adult HIV cohort in Nigeria. 
  • Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis. 
  • Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation. 
  • Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes. 
  • Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. 
  • Effect of Genetic African Ancestry on eGFR and Kidney Disease. 
  • Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease. 
  • Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. 
  • Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study design. 
  • Evolutionary genetics and acclimatization in nephrology. 
  • Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. 
  • Genetic Basis of Health Disparity in Childhood Nephrotic Syndrome. 
  • Genetic Modifiers of Sickle Cell Disease. 
  • HIV at 40: kidney disease in HIV treatment, prevention, and cure. 
  • HLA-DQA1 and APOL1 as Risk Loci for Childhood-Onset Steroid-Sensitive and Steroid-Resistant Nephrotic Syndrome. 
  • Host APOL1 genotype is independently associated with proteinuria in HIV infection. 
  • In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress. 
  • Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects. 
  • JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids. 
  • Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function. 
  • MYH9 and APOL1 are both associated with sickle cell disease nephropathy. 
  • Obesity and synergistic risk factors for chronic kidney disease in African American adults: the Jackson Heart Study. 
  • Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. 
  • Podocyte density is reduced in kidney allografts with high-risk APOL1 genotypes at transplantation. 
  • RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.